Trial Profile
A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma of the gastrointestinal tract.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2012
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Irinotecan (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Aug 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 18 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 Dec 2005 New trial record.